Back in 2000, newly merged GlaxoSmithKline PLC began to reorganize its R&D to boost productivity. Over the following decade and a half, the big pharma experimented with variously sized discovery units, oversight structures and incentive systems designed to create biotech-like innovation within its walls. (See Exhibit 1.)
It was a ripe time to try. Scientific discovery has flourished since the turn of the century. Genomics and gene-editing tools and other new technologies and advances in data science...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?